NCT02389530View on ClinicalTrials.gov

Use of Fluorescein Dye for the Removal of Brain Tumors

CompletedOBSERVATIONAL
Enrollment

91

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Brain Neoplasms
Interventions
DRUG

Fluorescein

Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.

Trial Locations (1)

15232

UPMC Shadyside Hospital, Pittsburgh

All Listed Sponsors
lead

University of Pittsburgh

OTHER

NCT02389530 - Use of Fluorescein Dye for the Removal of Brain Tumors | Biotech Hunter | Biotech Hunter